Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 89.94
Bid: 93.35
Ask: 93.36
Change: 0.08 (0.089%)
Spread: 0.01 (0.011%)
Open: 90.23
High: 90.59
Low: 89.73
Prev. Close: 89.86
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

European shares seen lower

Tue, 31st Jan 2023 07:36

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

EUROPEAN SHARES SEEN LOWER (0730 GMT)

European shares were set to open lower on Tuesday ahead of preliminary GDP readings, which investors will be watching closely to assess how the region's economy is going just as the European Central Bank prepares to raise rates again this week.

EuroSTOXX50 futures fell 0.3% following losses in Asia, where angst over upcoming central bank decisions, including also from the Federal Reserve, weighed after a strong start of the year. U.S. futures were broadly unchanged.

It's also a big week for earnings. Swiss bank UBS beat estimates in its latest quarter, but predicted an "uncertain" year ahead, plagued by accelerating inflation and higher rates. Its shares were seen rising slightly.

In Asia, Samsung Electronics indicated it did not plan to cut investment in chips, even after the South Korean group posted its smallest quarterly profit in eight years.

Later on in the U.S., Exxon Mobil is the first of the oil majors to report, while drugmaker Pfizer and automotive group GM also release quarterly numbers.

MIND THE GAP (0656 GMT)

An impressive 6% rally in global stocks this month, the first gain in January after three years, has got investors all excited after a dismal 2022.

Fundamentally, prospects for the world economy are not as bad as feared just a few months ago, prompting the International Monetary Fund to raise its 2023 global growth outlook slightly.

The IMF cited "surprisingly resilient" demand in the United States and Europe, easing of energy costs and the reopening of China's economy.

Still, it would be wise for investors to be mindful of a gap between expectations and reality.

On Monday, hotter-than-expected inflation data from Spain and an unexpected decline in the German economy in the fourth quarter created uneasiness for stock bulls, dragging down European shares.

Asian equities fell 1% on Tuesday and the dollar was eyeing a fourth monthly loss as investors reckon a peak in U.S. interest rates could swing into view as soon as this week's Federal Reserve meeting.

Flash GDP numbers are due from the euro zone, along with growth data for France and Italy. The numbers are likely to be keenly watched for signs on how weary economies are faring.

The ECB is all but certain to raise rates by half a percentage point on Thursday but fresh inflation data is still crucial for the central bank's policy guidance for subsequent meetings.

The Bank of England is set to raise rates by 50 bps to 4.0%, respectively. Headline inflation moderated in December to 10.5%, but it's still over five times its official target.

Money market bets show that the U.S. Federal Reserve is set to raise its policy rate by 25 basis points to 4.50%-4.75% on Wednesday.

Adding to pressure on British finance minister Jeremy Hunt to come up with a growth plan, the country became the only Group of Seven nation to suffer a cut to its 2023 economic growth outlook in IMF forecasts published on Tuesday.

Britain's flagging economy now appears set to shrink by 0.6% this year, a sharp downgrade from previously expected growth of 0.3% in the IMF's last forecast in October.

Meanwhile, a U.S. federal appeals court ruled on Monday that drug manufacturers can limit healthcare providers' use of outside pharmacies for dispensing drugs under a federal drug discount programme, marking a victory for Sanofi, Novo Nordisk and AstraZeneca.

Finally, there's good news for tech staff. With thousands of layoffs taking place in Silicon Valley, some German companies, faced with a tight labour market and a shortage of workers with key software engineering skills, are seizing on the West Coast's woes as an opportunity to recruit top talent.

Key developments that could influence markets on Tuesday:

Economic data: Euro zone Q4 flash GDP; France Q4 GDP, Jan CPI flash; Germany Dec import prices, retail sales, flash CPI; Italy preliminary Q4 GDP

Speakers: Swedish central bank governor Erik Thedeen participates in an open hearing on financial stability in the Swedish economy in Stockholm

European results: UBS, Swedbank

U.S. economic data: Q4 employment wages, Q4 Nov house prices

U.S. Federal Reserve begins two-day meeting

U.S. results: Exxon Mobil, Caterpillar, General Motors, Pfizer, McDonald's, UPS

More News
10 Jul 2023 19:33

EU investigates Ozempic, weight-loss drug Saxenda after suicidal thoughts reported

July 10 (Reuters) - The European Medicines Agency (EMA) is investigating Novo Nordisk's diabetes drug Ozempic and weight-loss treatment Saxenda after Iceland's health regulator flagged three cases of patients thinking about suicide or self-harm.

Read more
5 Jul 2023 12:04

China extends squeezed-out foreign pharmaceuticals firms an olive branch

BEIJING, July 5 (Reuters) - China's Commerce Minister told foreign pharmaceuticals firms they can expect "more development opportunities" during a roundtable on Wednesday, his ministry said, as drugmakers bemoan government procurement policies pricing them out of the market.

Read more
30 Jun 2023 22:38

First trial over Zantac cancer claims set for November

June 30 (Reuters) - The first U.S. trial over claims that discontinued heartburn drug Zantac causes cancer is now expected to take place in California state court on Nov. 13, a lawyer for plaintiffs in the litigation said Friday.

Read more
29 Jun 2023 06:30

Sanofi says it's back to the drawing board on mRNA flu vaccines

June 29 (Reuters) - Sanofi said that trials show the currently available mRNA technology behind the most successful COVID-19 shots will not be effective against influenza and it is already working on a next generation of shots.

Read more
23 Jun 2023 20:24

GSK soothes investors by settling first Zantac cancer lawsuit due for US trial

GSK shares best performer on London's stock market

*

Read more
22 Jun 2023 14:02

Novo Nordisk says EMA raised safety signal on drugs including semaglutide

Signal included drugs from Eli Lilly, AstraZeneca, Sanofi

*

Read more
22 Jun 2023 08:54

Novo Nordisk shares slip on EMA drug safety signal

COPENHAGEN, June 22 (Reuters) - Novo Nordisk said on Thursday the European Union's drug watchdog had last month raised a thyroid cancer safety signal for several of its drugs including semaglutide, the active ingredient in its popular diabetes and obesity drugs, Ozempic and Wegovy.

Read more
20 Jun 2023 17:44

China-exposed miners, luxury shares drag STOXX 600 down; Lanxess plunges

China-exposed miners and luxury stocks weigh

*

Read more
31 May 2023 23:35

US FDA approves Pfizer's RSV vaccine

May 31 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's respiratory syncytial virus (RSV) vaccine for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors.

Read more
27 Apr 2023 12:36

AstraZeneca increases bets on China as COVID vaccine sales fade

AstraZeneca already biggest drugmaker in China

*

Read more
27 Mar 2023 23:51

Amgen-Sanofi patent case divides makers of antibody drugs

March 27 (Reuters) - Amgen Inc's battle with Sanofi and Regeneron at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape U.S. patent law and competition among companies that make antibody medicines.

Read more
24 Mar 2023 15:25

GSK loses bid to keep experts out of upcoming Zantac trial

March 24 (Reuters) - A California judge on Thursday denied GSK Plc's bid to keep expert testimony linking its discontinued heartburn drug Zantac to cancer out of an upcoming trial, a setback for the British drugmaker facing lawsuits over the medicine in courts across the United States.

Read more
23 Mar 2023 17:09

Banks drag European shares down as c.banks join Fed in raising rates

Banks down 2.4%, rate-sensitive tech up 2.2%

*

Read more
20 Mar 2023 06:00

Vaccine makers prep bird flu shot for humans 'just in case'; rich nations lock in supplies

LONDON, March 20 (Reuters) - Some of the world's leading makers of flu vaccines say they could make hundreds of millions of bird flu shots for humans within months if a new strain of avian influenza ever jumps across the species divide.

Read more
13 Mar 2023 17:13

European stocks log steepest one-day fall this year as banks extend slide

European banks log worst two-day selloff in a year

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.